Savara Inc (OQ:SVRA)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 6836 BEE CAVE ROAD
BUILDING 3, SUITE 201
AUSTIN TX 78746
Tel: N/A
Website: savarapharma.com
IR: See website
<
Key People
Matthew Pauls
Chairman of the Board, Chief Executive Officer
David L. Lowrance
Chief Financial & Administrative Officer, Secretary
Robert Matthew Lutz
Chief Operating Officer
Raymond Dennis Pratt
Chief Medical Officer
   
Business Overview
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Financial Overview
For the fiscal year ended 31 December 2023, Savara Inc revenues was not reported. Net loss increased 43% to $54.7M. Higher net loss reflects pharmaceuticals segment loss increase of 55% to $60M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.25 to -$0.33.
Employees: 37 as of Mar 7, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $525.76M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$59.93M as of Dec 31, 2023
Net annual income (TTM): -$54.70M as of Dec 31, 2023
Free cash flow (TTM): -$51.36M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 138,148,141 as of Mar 7, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.